Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...
Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...
Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback